---
document_datetime: 2025-12-02 06:50:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/abasaglar.html
document_name: abasaglar.html
version: success
processing_time: 0.1104773
conversion_datetime: 2025-12-28 15:05:35.720989
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Abasaglar (previously Abasria)

[RSS](/en/individual-human-medicine.xml/65440)

##### Authorised

This medicine is authorised for use in the European Union

insulin glargine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Abasaglar (previously Abasria)](#news-on)
- [Related content](#related-content-439)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Abasaglar. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Abasaglar.

For practical information about using Abasaglar, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Abasaglar and what is it used for?

Abasaglar is a medicine that contains the active substance insulin glargine. It is used in adults and children over the age of two for the treatment of diabetes.

Abasaglar is a 'biosimilar medicine'. This means that Abasaglar is similar to a biological medicine (also known as the 'reference medicine') that is already authorised in the European Union (EU). The reference medicine for Abasaglar is Lantus.

## How is Abasaglar used?

Abasaglar is available as cartridges and prefilled disposable pens (KwikPen) and can only be obtained with a prescription. It is given by injection under the skin in the abdominal wall (tummy), the thigh, or the deltoid region (upper arm). The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the insulin work less well than expected.

Abasaglar is given once a day at the same time each day. The dose is adjusted individually, and the patient's blood glucose (sugar) should be regularly tested to find the lowest effective dose. Abasaglar can also be given together with diabetes medicines taken by mouth in patients who have type-2 diabetes.

Patients can inject themselves with Abasaglar if they have been trained appropriately.

For further information, see the package leaflet.

## How does Abasaglar work?

Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose. Abasaglar is a replacement insulin that is very similar to the insulin made by the body. The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.

The active substance in Abasaglar, insulin glargine, is produced by a method known as 'recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce insulin glargine.

Insulin glargine is slightly different from human insulin. The change means that it is absorbed more slowly and regularly by the body after an injection, and that it has a long duration of action.

## What benefits of Abasaglar have been shown in studies?

Studies were carried out to show that the way Abasaglar is absorbed into the body and the way it acts on blood glucose were similar toLantus. In addition, treatment with once-daily Abasaglar has been shown to be comparable to the reference medicine, Lantus, in two supportive studies involving a total of 1,295 adults with diabetes. In both studies, the main measure of effectiveness was the change after 6 months of treatment in the level in the blood of a substance called glycosylated haemoglobin (HbA 1c ), which gives an indication of how well blood glucose is controlled.

- In one study, Abasaglar was compared with Lantus when added to short-acting insulin treatment in 536 patients with type 1 diabetes. Their average HbA 1c before treatment was 7.8% and the average fall after 6 months was similar (0.35% in the Abasaglar group and 0.46% in the Lantus group); 34.5% of those given Abasaglar, and 32.2% of those given Lantus were below the target of 7%.

In the second study, treatment with Abasaglar or Lantus was compared in 759 patients with type 2 diabetes, as an addition to diabetes medicines taken by mouth. Average starting HbA 1c was 8.3%, and this fell to below 7% in 48.8% of those given Abasaglar, and 52.5% of those given Lantus, with an average percentage point fall of 1.29 and 1.34 respectively.

## What are the risks associated with Abasaglar?

The most common side effect with Abasaglar (which may affect more than 1 in 10 people) is hypoglycaemia (low blood glucose). Reactions at the site of the injection (redness, pain, itching and swelling) and skin reactions (rash) have been seen more often in children than in adults. For the full list of all side effects and restrictions with Abasaglar, see the package leaflet.

## Why is Abasaglar approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Abasaglar has been shown to have a comparable quality, safety and effectiveness to Lantus. Therefore, the CHMP's view was that, as for Lantus, the benefit outweighs the identified risk. The Committee recommended that Abasaglar be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Abasaglar?

A risk management plan has been developed to ensure that Abasaglar is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Abasaglar, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the [Abasaglar (previously Abasria) : EPAR - Risk-management-plan summary](/en/documents/rmp-summary/abasaglar-previously-abasria-epar-risk-management-plan-summary_en.pdf) .

## Other information about Abasaglar

The European Commission granted a marketing authorisation valid throughout the European Union for Abasria on 9 September 2014. The name of the medicine was changed to Abasaglar on 3 December 2014.

For more information about treatment with Abasaglar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Abasaglar (previously Abasria) : EPAR - Medicine overview

Reference Number: EMA/434801/2020

English (EN) (124.21 KB - PDF)

**First published:** 14/10/2014

**Last updated:** 14/12/2020

[View](/en/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-251)

български (BG) (149.45 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/bg/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_bg.pdf)

español (ES) (123.99 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/es/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_es.pdf)

čeština (CS) (148.69 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/cs/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_cs.pdf)

dansk (DA) (122.96 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/da/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_da.pdf)

Deutsch (DE) (127.5 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/de/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_de.pdf)

eesti keel (ET) (112.02 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/et/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.14 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/el/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_el.pdf)

français (FR) (126.15 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/fr/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_fr.pdf)

hrvatski (HR) (147.84 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/hr/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_hr.pdf)

italiano (IT) (123.08 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/it/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (154.3 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/lv/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (148.24 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/lt/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_lt.pdf)

magyar (HU) (145.96 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/hu/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_hu.pdf)

Malti (MT) (150.54 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/mt/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_mt.pdf)

Nederlands (NL) (124.53 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/nl/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_nl.pdf)

polski (PL) (150.66 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/pl/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_pl.pdf)

português (PT) (124.68 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/pt/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_pt.pdf)

română (RO) (144.26 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/ro/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_ro.pdf)

slovenčina (SK) (148.32 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/sk/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145.91 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/sl/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_sl.pdf)

Suomi (FI) (121.79 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/fi/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_fi.pdf)

svenska (SV) (122.56 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/12/2020

[View](/sv/documents/overview/abasaglar-previously-abasria-epar-medicine-overview_sv.pdf)

Abasaglar (previously Abasria) : EPAR - Risk-management-plan summary

English (EN) (46.03 KB - PDF)

**First published:** 14/10/2014

**Last updated:** 20/01/2015

[View](/en/documents/rmp-summary/abasaglar-previously-abasria-epar-risk-management-plan-summary_en.pdf)

## Product information

Abasaglar : EPAR - Product Information

English (EN) (1.67 MB - PDF)

**First published:** 14/10/2014

**Last updated:** 24/09/2021

[View](/en/documents/product-information/abasaglar-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-624)

български (BG) (1.35 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/bg/documents/product-information/abasaglar-epar-product-information_bg.pdf)

español (ES) (1.59 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/es/documents/product-information/abasaglar-epar-product-information_es.pdf)

čeština (CS) (1.8 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/cs/documents/product-information/abasaglar-epar-product-information_cs.pdf)

dansk (DA) (1.49 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/da/documents/product-information/abasaglar-epar-product-information_da.pdf)

Deutsch (DE) (1.63 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/de/documents/product-information/abasaglar-epar-product-information_de.pdf)

eesti keel (ET) (1.5 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/et/documents/product-information/abasaglar-epar-product-information_et.pdf)

ελληνικά (EL) (1.92 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/el/documents/product-information/abasaglar-epar-product-information_el.pdf)

français (FR) (1.64 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/fr/documents/product-information/abasaglar-epar-product-information_fr.pdf)

hrvatski (HR) (1.66 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/hr/documents/product-information/abasaglar-epar-product-information_hr.pdf)

íslenska (IS) (1.42 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/is/documents/product-information/abasaglar-epar-product-information_is.pdf)

italiano (IT) (1.64 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/it/documents/product-information/abasaglar-epar-product-information_it.pdf)

latviešu valoda (LV) (1.76 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/lv/documents/product-information/abasaglar-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.82 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/lt/documents/product-information/abasaglar-epar-product-information_lt.pdf)

magyar (HU) (1.71 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/hu/documents/product-information/abasaglar-epar-product-information_hu.pdf)

Malti (MT) (1.77 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/mt/documents/product-information/abasaglar-epar-product-information_mt.pdf)

Nederlands (NL) (1.68 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/nl/documents/product-information/abasaglar-epar-product-information_nl.pdf)

norsk (NO) (1.52 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/no/documents/product-information/abasaglar-epar-product-information_no.pdf)

polski (PL) (1.82 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/pl/documents/product-information/abasaglar-epar-product-information_pl.pdf)

português (PT) (1.45 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/pt/documents/product-information/abasaglar-epar-product-information_pt.pdf)

română (RO) (1.17 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/ro/documents/product-information/abasaglar-epar-product-information_ro.pdf)

slovenčina (SK) (1.81 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/sk/documents/product-information/abasaglar-epar-product-information_sk.pdf)

slovenščina (SL) (1.55 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/sl/documents/product-information/abasaglar-epar-product-information_sl.pdf)

Suomi (FI) (1.62 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/fi/documents/product-information/abasaglar-epar-product-information_fi.pdf)

svenska (SV) (1.41 MB - PDF)

**First published:**

14/10/2014

**Last updated:**

24/09/2021

[View](/sv/documents/product-information/abasaglar-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0037 10/09/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Abasaglar (previously Abasria) : EPAR - All Authorised presentations

English (EN) (16.94 KB - PDF)

**First published:** 14/10/2014

**Last updated:** 23/09/2020

[View](/en/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-230)

български (BG) (99.8 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/bg/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.16 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/es/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.39 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/cs/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.36 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/da/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (24.94 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/de/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (43.17 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/et/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.5 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/el/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_el.pdf)

français (FR) (41.37 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/fr/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (53.65 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/hr/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (33.54 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/is/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.13 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/it/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (91.48 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/lv/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (58.73 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/lt/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (41.95 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/hu/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (55.67 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/mt/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.67 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/nl/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (158.62 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/no/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.57 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/pl/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_pl.pdf)

português (PT) (24.53 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/pt/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.63 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/ro/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (103.26 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/sk/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.97 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/sl/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (21 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/fi/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.15 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

23/09/2020

[View](/sv/documents/all-authorised-presentations/abasaglar-previously-abasria-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Abasaglar (previously Abasria) Active substance insulin glargine International non-proprietary name (INN) or common name insulin glargine Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10AE04

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

## Authorisation details

EMA product number EMEA/H/C/002835

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Eli Lilly Nederland B.V.

Papendorpseweg 83

Opinion adopted 26/06/2014 Marketing authorisation issued 09/09/2014 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Abasaglar (previously Abasria) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (182.76 KB - PDF)

**First published:** 20/01/2015

**Last updated:** 24/09/2021

[View](/en/documents/procedural-steps-after/abasaglar-previously-abasria-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Abasaglar (previously Abasria)-H-C-PSUSA-00001751-201904 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/56836/2020

English (EN) (189.32 KB - PDF)

**First published:** 17/03/2020

[View](/en/documents/scientific-conclusion/abasaglar-previously-abasria-h-c-psusa-00001751-201904-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Abasria : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/340840/2014

English (EN) (1.58 MB - PDF)

**First published:** 14/10/2014

**Last updated:** 14/10/2014

[View](/en/documents/assessment-report/abasria-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Abasria

Adopted

Reference Number: EMA/CHMP/340931/2014

English (EN) (69.1 KB - PDF)

**First published:** 27/06/2014

**Last updated:** 27/06/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-abasria_en.pdf)

#### News on Abasaglar (previously Abasria)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 June 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-june-2014) 27/06/2014

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/09/2021

## Share this page

[Back to top](#main-content)